Cover Image
市場調查報告書

Cervarix(人類乳突病毒(HPV)預防疫苗)- 預測與市場分析

Cervarix (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 307135
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
Cervarix(人類乳突病毒(HPV)預防疫苗)- 預測與市場分析 Cervarix (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022
出版日期: 2014年03月31日 內容資訊: 英文 44 Pages
簡介

人類乳突病毒(HPV)最初的預防接種疫苗是在2006年開始使用的。全球HPN疫苗市場雖然目前已經確立,但在年輕女性這個傳統目標總族群的接種率依舊不高。當初HPN疫苗是針對子宮頸癌所開發、並上市的預防疫苗,但近年來由於HPV在其它癌症的作用日益解明,部分國家已經開始包括男性、廣泛地獎勵各階層接種疫苗。

本報告提供人類乳突病毒(HPV)疫苗──Cervarix調查分析,提供您疾病概要和治療指南,競爭情形,產品資訊,主要國家的銷售額預測等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
    • 病因
    • 病理生理學
  • 症狀

第4章 疫苗接種獎勵與接種率

  • 接種獎勵概要

第5章 競爭評估

  • 概要
  • 策略性競爭企業的評估

第6章 Cervarix

  • 概要
  • 功效
  • 安全性
  • SWOT分析
  • 預測

第7章 附錄

圖表

目錄
Product Code: GDHC387DFR

The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Merck's Gardasil, with GlaxoSmithKline's (GSK's) HPV vaccine Cervarix providing the only competition. The introduction of Merck's nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector.

Cervarix is manufactured and marketed by GSK, and consists of recombinant VLPs of the L1 capsid proteins from HPV strains 16 and 18, produced using a Baculovirus expression system. VLPs are combined with GSK's proprietary AS04 adjuvant, adsorbed on aluminum hydroxide. Cervarix is administered as a three-dose schedule with the second and third doses at one and six months following the first dose, respectively.

Scope

  • Overview of HPV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Cervarix including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Cervarix for the top nine countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Canada and Australia

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for HPV
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Cervarix performance
  • Obtain sales forecast for Cervarix from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Canada and Australia)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms

4. Vaccination Recommendations and Coverage Rates

  • 4.1. Vaccination Recommendations Overview

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Cervarix

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Vaccine Coverage
    • 7.4.2. Vaccine Approval versus Routine Schedule Inclusion
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
  • 7.5. Physicians and Specialists Included in this Study
  • 7.6. About the Author(s)
    • 7.6.1. Author(s)
    • 7.6.2. Therapy Area Director
    • 7.6.3. Global Head of Healthcare
  • 7.7. About GlobalData
  • 7.8. Disclaimer

List of Tables

  • Table 1: Histological Progression Towards Cervical Cancer
  • Table 2: Diseases Associated with HPV Infection and Their Associated Symptoms
  • Table 3: HPV Vaccine Recommendation Agencies by Country
  • Table 4: Targeted Group(s) for Recommended Immunization and Most-Administered HPV Vaccine by Country in the Global Markets, 2014
  • Table 5: Marketed Vaccines for HPV, 2014
  • Table 6: Product Profile - Cervarix
  • Table 7: Phase III Efficacy Trials - Cervarix
  • Table 8: Safety Profile - Cervarix
  • Table 9: Cervarix SWOT Analysis, 2014
  • Table 10: Global Sales Forecasts ($m) for Cervarix, 2012-2022
  • Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
Back to Top